Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies-Reference-Cited by-同舟云学术

Metabolism and excretion of (S)-6-(3-cyclopentyl-2-(4-trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid (PF-04991532), a hepatoselective glucokinase activator, in humans: confirmation of the MIST potential noted in first-in-Human metabolite scouting studies

Published:2019-03-07 Issue:12 Volume:49 Page:1447-1457
ISSN:0049-8254
Container-title:Xenobiotica
language:en
Short-container-title:Xenobiotica

Author:

Sharma Raman¹,Bergman Arthur²,Litchfield John³,Atkinson Karen¹,Kazierad David J.⁴,Kalgutkar Amit S.³

Affiliation:

1. Medicine Design Pfizer Worldwide Research and Development, Groton, CT, USA;

2. Clinical Pharmacology/Pharmacometrics Pfizer Worldwide Research and Development, Groton, CT, USA;

3. Medicine Design Pfizer Worldwide Research and Development, Cambridge, MA, USA;

4. Clinical Sciences Pfizer Worldwide Research and Development, Cambridge, MA, USA

Funder

Pfizer

Publisher

Informa UK Limited

Subject

Health, Toxicology and Mutagenesis,Pharmacology,Toxicology,Biochemistry,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/00498254.2019.1581960

Reference22 articles.

1. Generation of Major Human Excretory and Circulating Drug Metabolites Using a Hepatocyte Relay Method

2. THE VALUE OF METABOLITE IDENTIFICATION AND QUANTIFICATION IN CLINICAL STUDIES. SOME CASE STUDIES ENABLING EARLY ASSESSMENT OF SAFETY IN HUMANS

3. A Novel Relay Method for Determining Low-Clearance Values

4. In Vitro–In Vivo Correlation for Low-Clearance Compounds Using Hepatocyte Relay Method

5. The Hepatoselective Glucokinase Activator PF-04991532 Ameliorates Hyperglycemia without Causing Hepatic Steatosis in Diabetic Rats

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empirical scaling factor for predicting human pharmacokinetic profiles of disproportionate metabolites using the Css–MRTpo method and chimeric mice with humanised livers;Xenobiotica;2023-09-02

2. Mass Balance of the Indoleamine 2,3‐Dioxygenase Inhibitor Navoximod (GDC-0919) in Rats and Dogs: Unexpected Cyanide Release from Imidazo[5,1-a]isoindole and Species Differences in Glucuronidation;Drug Metabolism and Disposition;2023-04-14